Abstracts tagged "Interleukins"

Abstract Number: 1152 • ACR Convergence 2020
IL-18: A Biomarker That Reflects Disease Activity, Could It Be the Next Disease Activity Measure in Systemic Juvenile Idiopathic Arthritis?
Shima Yasin¹, Thuy Do², Sanjeev Dhakal², Elizabeth Baker², Alexei Grom³ and Grant Schulert⁴, ¹Cincinnati Children's Hospital Medical Center, Liberty twp, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood arthritis with prominent innate immune activity. Disease presentation and flares could largely mimic infections with fever…
Abstract Number: 1383 • ACR Convergence 2020
Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
Yasir Suleman¹, Kristina Clark², Svetlana Nihtyanova³, Voon Ong⁴ and Christopher Denton², ¹Royal Free Hospital London NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom, ³Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ⁴UCL, London, United Kingdom
Background/Purpose: Recent Phase II (faSScinate) and Phase III (focuSSced) clinical trials of tocilizumab versus placebo in early dcSSc highlighted the potential impact of tocilizumab on…
Abstract Number: 0505 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial
Xenofon Baraliakos¹, Laure Gossec², Effie Pournara³, Slawomir Jeka⁴, Ricardo Blanco⁵, Salvatore D'Angelo⁶, Georg Schett⁷, Barbara Schulz³, Michael Rissler³, Dermot Whyms⁸, Chiara Perella³ and Laura Coates⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴2nd Univ Hospital, CM UMK, Bydgoszcz, Poland, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Rheumatology Department of Lucania and Rheumatology Institute of Lucania (IRel), San Carlo Hospital of Potenza, Potenza, Italy, ⁷Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁸Novartis Ireland Limited, Dublin, Ireland, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Axial disease may affect up to 25–70% of psoriatic arthritis (PsA) patients, depending on the definition used. Current evidence on efficacy of biologics in…
Abstract Number: 1156 • ACR Convergence 2020
Comparison of Immunological Biomarkers and Lung Histology in Patients with Elevated IL18 – Pulmonary Alveolar Proteinosis and Recurrent Macrophage Activation Syndrome (IL-18PAP-MAS) and Other Inflammatory Lung Diseases
Alhanouf Alsaleem¹, Adriana de Jesus², Sofia Torreggiani³, Chyi-Chia Lee⁴, Les Folio⁵, Huy Do⁶, Andrew Oler⁷, Caroline Kim³, Stewart Levine⁸, Anthony Suffredini⁹, Cem Gabay¹⁰, Joseph Fontana¹¹, Scott Canna¹² and Raphaela Goldbach-Mansky¹³, ¹Division of Pediatric Rheumatology, Department of pediatrics, King Faisal specialist hospital and research center, Riyadh, Saudi Arabia, RiYADH, Saudi Arabia, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ³Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ⁴Pathology Department/NCI/NIH, Bethesda, MD, ⁵Radiology and Imaging Services/NIH, Bethesda, MD, ⁶Radiology and Imaging Sciences, Bethesda, MD, ⁷Bioinformatics and Computational Biosciences Branch/NIAID/NIH, Bethesda, MD, ⁸Laboratory of Asthma and Lung Inflammation, Division of Intramural Research, NHLBI, NIH,, Bethesda, MD, ⁹Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD, ¹⁰University Hospitals of Geneva, Geneva, Switzerland, ¹¹NHLBI/NIH, Bethesda, MD, ¹²University of PIttsburgh, Pittsburgh, PA, ¹³Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: Recently, pulmonary alveolar proteinosis (PAP) and recurrent macrophage activation syndrome (MAS) have been reported in rare patients (pts) with systemic juvenile idiopathic arthritis (SJIA)…
Abstract Number: 1399 • ACR Convergence 2020
Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines
Ching-Huang Ho¹, Andrea Silva¹ and I-Cheng Ho², ¹Brigham and Women's Hospital, Boston, MA, ²Birgham and Women's Hospital, Boston, MA
Background/Purpose: Inhibition of TNFα has emerged as an effective therapeutic approach for many autoimmune/inflammatory diseases.While the efficacy and safety profile of the five FDA-approved TNFis…
Abstract Number: 0507 • ACR Convergence 2020
Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study
Grace Wright¹, Peter Nash², Laura Coates³, Jordi Gratacós⁴, Frank Behrens⁵, Kevin Ding⁶, Weibin Bao⁷, Luminita Pricop⁶, Corine Gaillez⁸ and Iain McInnes⁹, ¹Association of Women in Rheumatology, New York, NY, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Oxford, Oxford, United Kingdom, ⁴University Hospital Parc Tauli Sabadell, Barcelona, Spain, ⁵CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁶Novartis Pharmaceuticals Corporation, East Hanover, ⁷Novartis Pharmaceuticals Corporation, East Hannover, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Lower efficacy to anti-tumor necrosis factor treatment has been reported in female patients with psoriatic arthritis (PsA) as compared to males in clinical registries.1…
Abstract Number: 1157 • ACR Convergence 2020
Health and Socioeconomic Outcomes in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed for a Median of Fifteen Years
Sara Alehashemi¹, Megha Garg², Kim Johnson³, Kelly King⁴, Chris Zalewski⁴, Debbie Payne⁵, Adriana de Jesus⁶, Joseph Snow⁷, Wadih Zein⁵, M. Teresa Magone⁵, Rachel Bishop⁸, Carmen Brewer⁴, Jeff Kim⁴, Scott Paul⁹, John Butman¹⁰ and Raphaela Goldbach-Mansky¹¹, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ²NIH/NIAID, Rochester, NY, ³NIH, NIAID, Bethesda, ⁴NIH, NIDCD, Bethesda, MD, ⁵NIH/NEI, Bethesda, MD, ⁶Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ⁷NIH, NIMH, Bethesda, MD, ⁸NIH, NEI, Bethesda, MD, ⁹NIH, CC/RMD, Bethesda, MD, ¹⁰NIH, CC/DRD, Bethesa, MD, ¹¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: Patients (pts) with NOMID have systemic inflammation and organ damage such as sensorineural hearing loss, hydrocephalus, optic nerve atrophy and growth plate defects. IL-1 blocking…
Abstract Number: 1479 • ACR Convergence 2020
Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry
Jasmin Kuemmerle-Deschner¹, Birgit Kortus-Goetze², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Ales Janda⁶, Tilmann Kallinich⁷, Prasad T. Oommen⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Norbert Blank¹², ¹University Hospital Tuebingen, Tuebingen, Germany, ²Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Department of Pediatrics, University Hospital Ulm, Germany, Ulm, Germany, ⁷Charite, Berlin, Germany, ⁸Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany
Background/Purpose: In the treatment of monogenic autoinflammatory diseases (AID), a heterogeneous group of diseases with excessive interleukin (IL)-1β release and severe systemic and organ inflammation,…
Abstract Number: 0644 • ACR Convergence 2020
Characterizations of Cytokine Storm Associated with COVID19
Ofer Perzon¹, Avi Abutbul¹, Sigal Sviri¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: COVID-19, the name given to the clinical syndrome associated with the newly recognized virus SARS-CoV-2 has become pandemic with mortality estimated based on reports…
Abstract Number: 1214 • ACR Convergence 2020
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies
John Tesser¹, Grace Wright², Vibeke Strand³, Jeffrey Kaine⁴, Karina Maslova⁵, Gregory St John⁶, Kerri Ford⁵, Amy Praestgaard⁵ and Ernest Choy⁷, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Association of Women in Rheumatology, New York, NY, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Independent Rheumatology Consultant, Sapphire, NC, ⁵Sanofi, Cambridge, MA, ⁶Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Evaluation of response to RA therapy at 12 weeks after initiation is recommended in treatment guidelines. CRP response after 12 weeks of therapy may…
Abstract Number: 1519 • ACR Convergence 2020
Interleukin-17D, a Cytokine Derived from Stromal Cells, Attenuates Joint Inflammation
Sijia Chen¹, Catherine Manning², Melissa van Tok³, Yukiko Maeda⁴, Daniel Montoro⁵, Jung-Min Kim⁶, Jeroen den Dunnen³, Nataliya Yeremenko³, Jae-Hyuck Shim⁴, Dominique Baeten⁷ and Ellen Gravallese⁸, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women’s Hospital, Boston, ³Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴University of Massachusetts Medical School, worcester, MA, ⁵Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, ⁶University of Massachusetts Medical School, Worcester, ⁷UCB Pharma / Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Interleukin(IL)-17D is a little recognized member of the IL-17 family of cytokines. While the activities of IL-17A and IL-17F in the pathogenesis of spondyloarthritis…
Abstract Number: 0040 • ACR Convergence 2020
Whole Blood RNA Expression in Clinically Suspected Arthralgia Patients Shows a Potential Value in Prediction of Inflammatory Arthritis
Ellis Niemantsverdriet¹, Erik van den Akker¹, Debbie Boeters¹, Susan van den Eeden¹, Annemieke Geluk¹ and Annette van der Helm - van Mil², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA)-patients have differently expressed genes involved in cytokine/chemokine-mediated immunity compared to healthy controls, which are changed years before RA-diagnosis. It is unclear,…
Abstract Number: 0811 • ACR Convergence 2020
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
Janet Pope¹, Amy Praestgaard², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez², Serge Perrot⁴, Yvonne Lee⁵, Anthony Sebba⁶ and Ernest Choy⁷, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Sanofi, Cambridge, MA, ³Sanofi, Bridgewater, NJ, ⁴Paris Descartes University, Paris, Ile-de-France, France, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Arthritis Associates, Palm Harbor, Tampa, FL, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Prescription opioids are routinely used in patients with RA. However, use of opioids should be minimized to prevent abuse and addiction. Chronic opioid use…
Abstract Number: 1224 • ACR Convergence 2020
Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab
Esteban Rubio Romero¹, Alejandro Muñoz Jiménez², Rosalia Martinez Perez³ and Lara Mendez Diaz⁴, ¹VIRGEN DEL ROCIO UNIVERSITY HOSPITAL, SEVILLE, Spain, ²H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ³Virgen del Rocío University Hospital, seville, Spain, ⁴Virgen del Rocío Hospital, sevilla, Spain
Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…
Abstract Number: 1632 • ACR Convergence 2020
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry
Joerg Henes¹, Norbert Blank², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Markus Hufnagel⁶, Tilmann Kallinich⁷, Birgit Kortus-Goetze⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Jasmin Kuemmerle-Deschner¹², ¹Department of Internal Medicine II, Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center, Medical Faculty, University of Freiburg, Germany, Freiburg, Germany, ⁷Charite, Berlin, Germany, ⁸Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Autoinflammatory periodic fever syndromes characterized by excessive interleukin(IL)-1ß release and severe systemic and organ inflammation have been successfully treated with the anti-IL-1ß inhibitor canakinumab.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].